论文部分内容阅读
目的探讨巴柳氮钠片(贝乐司)对未确定型结肠炎的临床疗效。方法收集2006年6月至2006年12月我院诊断为未确定型结肠炎患者86例,随机分为巴柳氮钠治疗组A组46例和对照组B组40例。A组患者口服巴柳氮钠片剂1.0g/次,2次/d,连续4周。B组服用止痛及止泻药物等对症治疗。在治疗前后比较两组患者的临床症状(腹痛、腹泻、大便次数或/和性状改变)大便带黏液甚至有脓血、里急后重,生化指标(肝功能、肾功能、血沉、C-反应蛋白等)以及结肠镜下黏膜和组织学表现。结果2周后A组可迅速缓解患者的临床症状(腹痛、腹泻、大便带黏液),4周后改善内镜下黏膜炎症表现以及降低黏膜组织炎症分级(P<0.05)。患者服用巴柳氮钠的依从性好,对患者的肝功能、肾功能无影响。结论巴柳氮钠对未确定型结肠炎治疗有效,且不良反应少。
Objective To investigate the clinical efficacy of balsalazide sodium tablets (bleb) in patients with unconfirmed colitis. Methods Totally 86 patients diagnosed as unconfirmed colitis in our hospital from June 2006 to December 2006 were randomly divided into two groups, 46 cases in group B and 40 cases in group B. A group of patients oral sodium balsalate tablets 1.0g / time, 2 times / d, for 4 weeks. Group B took analgesic and antidiarrheal drugs and other symptomatic treatment. Before and after treatment, clinical symptoms (abdominal pain, diarrhea, stool frequency and / or trait changes) were compared between the two groups before and after treatment. Stool with mucus and even sepsis, tenesmus, biochemical indicators (liver function, renal function, ESR, C- As well as colonoscopic mucosal and histological findings. Results After 2 weeks, the clinical symptoms (abdominal pain, diarrhea, stool with mucus) of group A were relieved rapidly. After 4 weeks, the symptoms of endoscopic mucosal inflammation were improved and the grade of mucosal inflammation was decreased (P <0.05). Patients taking balsalazide sodium compliance, the patient’s liver function, renal function had no effect. Conclusion Balsalazide sodium is effective in the treatment of patients with unconfirmed colitis with few adverse reactions.